Table 4.
Association of plasma sphingolipids with baseline fasting plasma insulin, HOMA-IR, and HOMA-B
| Sphingolipid | Outcome |
||
|---|---|---|---|
| Insulin | HOMA-IR | HOMA-B | |
| Cer-16 |
1.13 (1.07–1.20), 1.9 × 10−5 |
1.15 (1.08–1.22), 4.7 × 10−6 |
1.04 (0.99–1.11), 0.13 |
| Cer-18 |
1.11 (1.06–1.15), 1.0 × 10−6 |
1.12 (1.08–1.17), 6.3 × 10−8 |
1.04 (1.00–1.09), 0.03 |
| Cer-20 |
1.12 (1.07–1.17), 1.5 × 10−7 |
1.13 (1.08–1.18), 1.3 × 10−7 |
1.06 (1.02–1.11), 0.003 |
| Cer-22 |
1.13 (1.08–1.19), 3.9 × 10−7 |
1.15 (1.09–1.21), 1.0 × 10−7 |
1.07 (1.02–1.12), 0.004 |
| Cer-24 |
1.05 (0.99–1.11), 0.08 |
1.06 (1.00–1.13), 0.04 |
1.00 (0.94–1.05), 0.86 |
| SM-14 |
1.00 (0.96–1.05), 0.91 |
1.01 (0.96–1.06), 0.79 |
0.97 (0.93–1.01), 0.19 |
| SM-16 |
0.89 (0.81–0.97), 0.009 |
0.87 (0.79–0.96), 0.006 |
0.89 (0.82–0.98), 0.01 |
| SM-18 |
0.95 (0.89–1.02), 0.19 |
0.96 (0.89–1.03), 0.24 |
0.93 (0.87–0.99), 0.03 |
| SM-20 |
0.95 (0.89–1.02), 0.17 |
0.95 (0.89–1.02), 0.19 |
0.94 (0.88–1.00), 0.05 |
| SM-22 |
1.00 (0.93–1.07), 0.97 |
1.00 (0.93–1.08), 0.91 |
0.96 (0.90–1.03), 0.30 |
| SM-24 |
0.96 (0.90–1.02), 0.22 |
0.97 (0.90–1.03), 0.31 |
0.93 (0.87–0.99), 0.02 |
| GluCer-16 |
0.96 (0.90–1.02), 0.16 |
0.95 (0.89–1.02), 0.15 |
0.95 (0.89–1.00), 0.07 |
| GluCer-22 |
0.93 (0.87–0.98), 0.013 |
0.93 (0.87–0.98), 0.01 |
0.91 (0.86–0.97), 0.002 |
| GluCer-24 |
0.92 (0.86–0.97), 0.0023 |
0.92 (0.86–0.97), 0.004 |
0.90 (0.85–0.95), 0.0002 |
| LacCer-16 | 0.87 (0.82–0.94), 0.0001 | 0.86 (0.80–0.92), 3.7 × 10−5 | 0.91 (0.85–0.98), 0.007 |
Data are ratio of geometric means associated with twofold higher sphingolipid (95% CI), P value.